Pharmacogenetics and Pharmacogenomics in Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2026 | Viewed by 170
Special Issue Editor
Interests: pharmacogenomics; prostate; cancer; gene; target
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pharmacogenetics and pharmacogenomics are reshaping cancer therapeutics by enabling more precise, individualized treatment. These advances promise better efficacy, reduced toxicity, and meaningful progress in precision oncology. This Special Issue seeks high‑quality manuscripts exploring these scientific advances, as well as the real‑world challenges that accompany these advances.
We welcome submissions that address clinical applications of pharmacogenomic testing, innovative research methodologies, and emerging biomarkers that guide drug selection and dosing in oncology. Also encouraged are studies examining barriers to implementation across diverse settings, including ethical concerns, patient protections, cost considerations, and the infrastructural needs required for the sustainable integration of these tools into cancer care.
We look forward to receiving your contributions to advancing the future of equitable precision in cancer care.
Dr. Cheryl D. Cropp
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacogenetics
- pharmacogenomics
- precision oncology
- cancer care
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
